XENiOS Receives Eight-Figure Investment

Xenios-logoXENiOS AG, a Heilbronn, Germany-based commercial-stage medical device company, received an eight-figure investment from existing investors.

The exact amount of deal was not disclosed. The round was led by Zukunftsfonds Heilbronn (ZFHN), which typically invests up to €10m in any given transaction.

The company intends to use the funds to accelerate commercial expansion in Europe and the United States.

Led by Georg Matheis, Managing Director, XENiOS is a medical technology company comprised of two product brands, novalung® and i–cor®:
– XENiOS novalung offers the full spectrum of extrapulmonary lung support. One indication is COPD (Chronic Obstructive Pulmonary Disease) for which novalung therapies offer an alternative to injurious, immobilizing mechanical ventilation.
– XENiOS i-cor is focused on heart therapies. One indication is for Cardiogenic Shock, or Decompensated Heart Failure.

The company has clinically proven applications of its therapies with predictable execution. Regulatory approvals are in place (CE-marked, some products FDA-cleared, plus several Asian markets).

FinSMEs

24/09/2015

Join the discussion